Gut Microbiome

A recent study showed that gut microbiome composition may impact the severity of COVID-19. It was the top story in gastroenterology last week.

The gut microbiome potentially could serve as a biomarker to predict the efficacy of nivolumab among patients with advanced gastric cancer, according to results of the DELIVER trial presented at Gastrointestinal Cancers Symposium.

A healthy diet may be linked with gut microbes correlate with a lower risk developing conditions including obesity, type 2 diabetes and cardiovascular disease, according to a report published in Nature Medicine.

Fecal microbiome transfer led to a mean reduction in android-to-gynoid fat ratio and a resolution of metabolic syndrome in a cohort of adolescents with obesity, according to randomized controlled trial data published in JAMA Network Open.

Correlation between gut microbiota composition, cytokine levels and inflammatory markers among COVID-19 patients demonstrated the gut microbiome is linked with the severity of COVID-19, according to a study in Gut.

In this exclusive video, Colleen Cutcliffe, PhD, CEO and co-founder of Pendulum Therapeutics, discussed the latest findings regarding the microbiome.

This award goes to a physician or institution that changed the face of the gastroenterology practice. The awardee is seen as an example of how patient care can be bettered through changes in administration, technique or the delivery of value-based care.

The risk for developing type 2 diabetes rose with regular use of proton pump inhibitors, particularly for longer than 2 years, but the risk decreased when the drugs were discontinued, according to study results published in Gut.

Healio and Cardiology Today have compiled a list of the top-read news from the American Heart Association Hypertension Scientific Sessions.

Changes in the human gut microbiome after sleeve gastrectomy contribute to the negative skeletal impact of bariatric surgery among adults with obesity, according to a speaker.